Skip to main content

Table 2 The distribution of EMG-NCV (Median and IQR) in each group of study

From: Lithium and preventing chemotherapy-induced peripheral neuropathy in breast cancer patients: a placebo-controlled randomized clinical trial

Variable Group Start time
Median (IQR)
3rd month
Median (IQR)
9th month
Median (IQR)
P
Ulnar NCV Drug 65 (9) 42.5 (15.3) 55 (17) < 0.001
Placebo 68.5 (5) 40 (17.8) 52 (18.5) < 0.001
Ulnar Amp Drug 6.1 (1) 3 (2) 5.4 (1.2) < 0.001
Placebo 6.4 (1) 4 (1.5) 5 (2) < 0.001
Median NCV Drug 60 (18.5) 40 (18.5) 50 (14.5) < 0.001
Placebo 60.5 (10) 39 (17.5) 49.5 (18.3) < 0.001
Median Amp Drug 5.2 (1.4) 2.9 (2.1) 4.1 (2) < 0.001
Placebo 5 (1.6) 2.3 (2) 4.3 (2.3) < 0.001
Tibial NCV Drug 53.5 (10) 36.5 (16.5) 45.5 (8.3) < 0.001
Placebo 55 (7.5) 34.5 (19.3) 47.5 (13.3) < 0.001
Tibial Amp Drug 3 (0.1) 1.9 (1.3) 2.4 (0.8) < 0.001
Placebo 3 (0.2) 1.8 (1.2) 2.5 (1) < 0.001
Proneal NCV Drug 54 (11.5) 35 (13.3) 42.5 (12.5) < 0.001
Placebo 54.5 (10.8) 32 (11.5) 43.5 (15.9) < 0.001
Proneal Amp Drug 3 (0.3) 1.9 (1.3) 2.3 (0.7) < 0.001
Placebo 3 (0.1) 1.9 (0.9) 2.1 (1) < 0.001
  1. NCV nerve conduction velocity, Amp amplitude